CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center
Apa yang termasuk di paket ini
Prosedur Medis
- Terapi sel T CAR
- Tes darah
- Tes darah biokimia
- Biopsi
- CT Scan
- Konsultasi dengan dokter
- Konsultasi dengan ahli onkologi
- Konsultasi dengan ahli hematologi
- Konsultasi dengan ahli imunologi
- Konsultasi dengan dokter hematologi pediatrik
- Hitung darah lengkap dengan penanda kanker dan proteinogram
- CT angiografi
- Elektrokardiogram (EKG)
- Pemeriksaan tindak lanjut
- Perawatan pasca-operasi
- Tes prabedah
- PET/CT
- Konsultasi dengan onkohematologis
- layanan perawat 24 jam
- 3 kali makan per hari oleh ahli gizi
Durasi
- 21 hari di rumah sakit
Akomodasi
Rawat Inap
Transportasi
Transfer bandara-klinik-bandara
Informasi tambahan
CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center
For patients diagnosed with Acute Lymphoblastic Leukemia (ALL), especially those with relapsed or treatment-resistant disease, access to advanced therapy can be life-changing.
Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope where conventional treatments may no longer be effective.
Sheba is recognized as a global leader in CAR-T therapy for ALL, particularly in pediatric and young adult patients, combining cutting-edge science with extensive clinical experience.
A Faster Path to Life-Saving Treatment
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, critical in fast-progressing diseases like ALL.
• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reinfusion of modified cells designed to target and eliminate leukemia cells
By keeping the entire process in-house, treatment can begin in approximately 10 days, significantly faster than many international centers.
CAR-T therapy acts as a “living drug,” continuing to work in the body and offering the potential for deep and lasting remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.
Outstanding Outcomes That Offer Real Hope
Sheba is a world leader in pediatric CAR-T for ALL, with exceptional clinical results:
• Up to ~90% remission in pediatric patients
• ~80% in young adults (up to 23 years)
• ~70% in adult patients
These outcomes provide a powerful treatment option and a second chance for patients with limited alternatives.
Why Patients Choose Sheba
• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – specialized care with 24/7 monitoring
• Multidisciplinary expertise – hematology, oncology, and immunotherapy teams working together
• Full international support – medical review, travel coordination, and patient assistance
Comprehensive, Personalized Care
Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise, individualized treatment plan.
Services are available in English, Russian, and Arabic, providing a seamless experience for international patients and their families.
A Global Leader in Advanced Leukemia Care
By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for ALL worldwide, offering patients not just treatment, but a real opportunity for remission and renewed life.
Bantuan Bookimed 24/7
- Koordinator medis pribadi
- Pengaturan perjalanan medis — pemesanan tiket pesawat dan kamar hotel dengan harga mitra khusus
- Pendampingan pasien selama perjalanan medis
Harga program
Apa yang TIDAK termasuk di paket ini
Dokter
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Bagaimana pelayanan kami?
Tentang klinik
Terapi sel T CAR di Sheba Medical Center di Tel Aviv, Israel dapat memakan biaya sekitar $63.100 untuk program lengkap. Rumah sakit ini menempati peringkat 10 besar dunia dan menawarkan perawatan canggih ini di bawah pimpinan Prof. Arnon Nagler, seorang spesialis transplantasi sumsum tulang terkemuka.
Tentang Perawatan
Terapi sel T CAR adalah pendekatan inovatif untuk leukemia, limfoma, dan multipel mieloma. Prosedur ini melibatkan pengambilan sel T pasien, memodifikasinya secara genetik di laboratorium, dan memasukkannya kembali setelah kemoterapi. Proses ini memerlukan rawat inap selama 21 hari dengan kemungkinan perawatan di ICU.
Apa yang Termasuk
- Penilaian komprehensif ($5.000-$10.000)
- Pengambilan sel melalui aferesis ($6.600)
- Persiapan laboratorium untuk sel yang dimodifikasi ($20.000)
- Kondisi kemoterapi ($5.000)
- Rawat inap 21 hari ($31.500)
- Penilaian pasca-perawatan ($3.000-$5.000)
Persiapan dan Pemulihan
Pasien memerlukan biopsi sumsum tulang, pemindaian PET/CT, dan tes darah sebelum perawatan. Pemantauan harian untuk sindrom pelepasan sitokin dilakukan setelah infus. Total masa tinggal yang disarankan di Israel adalah 4-6 minggu. Perlu dicatat bahwa CAR-T untuk mieloma masih bersifat eksperimental.
Sheba Medical Center merawat 1,5 juta pasien setiap tahun dan menyediakan layanan multibahasa. Deposit sebesar $50.000-$60.000 diperlukan sebelum kedatangan. Hubungi rumah sakit untuk mendiskusikan apakah terapi ini sesuai dengan kondisi Anda.
Pembayaran & Reward
Anda tidak membayar layanan kami
Anda melakukan pembayaran langsung di klinik atau ke rekening resmi mereka.
Beberapa klinik mungkin meminta deposit sebagai bagian kebijakannya.
Bayar secara bertahap dengan opsi cicilan.
Dapatkan reward dengan mereferensikan teman ke Bookimed.